EUCTR2006-005841-13-HU进行中（未招募）不适用
Multicenter, open-label study to investigate the efficacy and safety of Cavinton Forte (vinpocetine) tablet in patients with mild cognitive impairment (MCI).
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Meet the diagnostic criteria of MCI (Mayo criteria)
- •Total score of MMSE is between 24-28.
- •Age between 35 and 70 years (both males and females).
- •18 kg/m2 = BMI = 35 kg/m2 (and the minimal body weight is 40 kg)
- •Education level is min. 6 classes.
- •Signed Inform Consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Severe vascular disease (for example: territorial stroke, TIA, clinically significant (>70%) carotis stenosis or occlusion) in medical history.
- •Severe dementia.
- •Uncontrolled hypertension (systolic > 180 Hgmm, diastolic > 110 Hgmm).
- •If QTc > 500 msec.
- •Any clinically significant abnormality in clinical laboratory tests. Screening haematology and biochemistry laboratory tests must be within defined limits including full blood count within the normal range (or not clinically significantly abnormal), liver enzymes not exceed three times the upper limit of normal range, alkaline phosphatase, bilirubin not exceed twice the upper limit of normal range.
- •Having received the investigational product (vinpocetine) during 1 month prior to the study. (In this case patient can be involved into the study after 1 month long wash-out period.)
- •Current treatment with drugs having cognitive effect in the central nervous system (for example: piracetam, nicergolin, pyritinol, metylphenidate, Gingko Biloba extracts) with patients unable or unwilling to be withdrawn from this medication before the trial.
- •A history of drug or alcohol abuse within the past 2 years or current chronic or intermittent users of illicit drugs.
- •Known hypersensitivity to vinpocetine or lactose intolerance.
- •Severe physical or mental concomitant disorder that might confound the conduct or result of the trial.
- •Depression (total score of Hamilton Depression Scale is more than 12).
- •Lactating or pregnant women or women of child-bearing potential without appropriate contraceptive treatment.
- •Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequences of the study or to cooperate on the necessary level.
- •Evidence of an uncooperative attitude.
- •Patients who have participated in a study of an investigational drug or device within 3 months of this study.
研究者
相似试验
进行中（未招募）
不适用
An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the combination of valsartan 160 mg plus amlodipine 5 mg in hypertensive patients not adequately responding to a 4 week treatment with amlodipine 5 mg or felodipine 5 mg in monotherapy - ExPress - Mmoderate essential hypertensionMedDRA version: M15Level: LLTClassification code 10015488EUCTR2006-001484-39-DEovartis Pharma GmbH230
进行中（未招募）
不适用
An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the fixed dose combination of valsartan 160 mg plus HCTZ 25 mg in hypertensive patients not adequately responding to a 4 week therapy with the free combination of an angiotensin receptor blocker (candersartan 32 mg) plus HCTZ 25 mg - CICEROEUCTR2006-001311-30-DEovartis Pharma GmbH220
进行中（未招募）
1 期
A study to to evaluate the efficacy, safety and tolerability of PDNO (nitrosooxypropanol) infusion in COVID-19 patients with high blood pressure in lung arteries.Acute pulmonary hypertension during COVID-19 infectionMedDRA version: 20.0Level: HLTClassification code 10037401Term: Pulmonary hypertensionsSystem Organ Class: 100000004855EUCTR2020-002982-33-SEAttgeno AB16
进行中（未招募）
不适用
An open-label, multicenter study to evaluate the efficacy and safety of a 5 week therapy with the combination of valsartan 160 mg plus amlodipine 10 mg in hypertensive patients not adequately responding to a 5 week therapy with ramipril 5 mg and felodipine 5 mgPatients with essential hypertensionMedDRA version: M15Level: LLTClassification code 10015488EUCTR2005-003976-39-DEovartis Pharma GmbH200
进行中（未招募）
不适用
An open-label, multicenter study to evaluate the efficacy and safety of a 4 week therapy with the single pill (SPC) combination of Aliskiren 300 mg / Amlodipine 10 mg in hypertensive patients not adequately respond to an uptitrated 4 week therapy with the SPC of Olmesartan 40 mg / Amlodipine 10 mg, with a potential extention if patients still not adequately respond with a 4 week therapy with the SPC Aliskiren 300 mg / Amlodipine 10 mg / HCTZ 12,5 mg - AWESOMEessential hypertensionMedDRA version: 12.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2009-016693-33-DEovartis Pharma GmbH